menu search

ITCI / Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings report showed substantial revenue growth driven by Caplyta's net product sales, although the company still recorded a net loss. The company's growth initiatives include exploring the potential of lumateperone in Major Depressive Disorder, developing new formulations, and expanding their pipeline with new programs. Read More
Posted: Aug 12 2023, 10:29
Author Name: Seeking Alpha
Views: 100971

ITCI News  

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

By Zacks Investment Research
November 3, 2023

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. more_horizontal

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

By Seeking Alpha
August 12, 2023

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed more_horizontal

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

By Zacks Investment Research
August 4, 2023

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. more_horizontal

Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)

By Seeking Alpha
May 25, 2023

Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)

Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schiz more_horizontal

Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

By Zacks Investment Research
March 31, 2023

Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? more_horizontal

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

By Zacks Investment Research
March 29, 2023

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. more_horizontal

Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

By Zacks Investment Research
March 29, 2023

Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate re more_horizontal

Why Intra-Cellular Therapies Climbed Tuesday

By The Motley Fool
March 28, 2023

Why Intra-Cellular Therapies Climbed Tuesday

Caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potential addition of major depressive disorder to th more_horizontal


Search within

Pages Search Results: